Two mutations in the α-synuclein gene (A30P and A53T) have been linked to autosomal
dominant early-onset Parkinson's disease (PD). Both mutations promote the formation of …

Amyloid β 1−42 (Aβ 1 - 42 ) is a self-associating peptide that becomes neurotoxic upon
aggregation. Toxicity originally was attributed to the presence of large, readily formed Aβ fibrils, …

Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …

Islet amyloid polypeptide (IAPP) and insulin are copackaged and cosecreted by pancreatic
islet β-cells. Non-insulin-dependent (type II) diabetes mellitus (NIDDM) is characterized by …

Corona Virus Disease 2019 (COVID-19) is a new illness caused by a novel coronavirus,
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms are variable but …

Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine
receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; …

Background and Objective To determine whether rituximab is safe and potentially beneficial,
warranting further investigation in an efficacy trial for acetylcholine receptor antibody-…

Familial amyotrophic lateral sclerosis (FALS) is a fatal motor neuron disease that is caused
by mutations in the gene encoding superoxide dismutase-type 1 (SOD1). The affected …

During the COVID-19 pandemic, patients with neuromuscular disorders, especially patients
with autoimmune myasthenia gravis, might be at greater risk of worse outcomes than other …

Background: A subset of myasthenia gravis (MG) patients is refractory to standard therapies.
Identifying the characteristics of this population is essential as newer treatment strategies …